EUCTR2005-001243-28-DE进行中（未招募）不适用
Study to determine the non inferiority of GROUP I (high need”) compared to GROUP II (low need”) concerning the efficacy of infliximab with respect to safety and tolerability in patients suffering from chronic plaque psoriasis (psoriasis vulgaris). - Infliximab in high need versus low need psoriasis patients – IHELP-study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient Inclusion Criteria
- •The patient must meet the ALL criteria listed below for entry:
- •Patient Inclusion Criteria at Screening Visit (Visit 0)
- •1. Written informed consent by the patient for study participation, prior to protocol specific procedures.
- •2. Patients who are 18 years of age or older at time of enrolment, may be male or female and of any race.
- •3. Diagnosis of plaque-type psoriasis (psoriasis vulgaris) at least 6 months prior to screening.
- •4. Plaque-type psoriasis covering at least 10% of total body surface area.
- •5. PASI-Score of 12 or greater.
- •6. GROUP I (high need”) patients:
- •Adult patients with moderate to severe plaque psoriasis who are either not controlled by, or are intolerant to or have contraindications to at least two currently available systemic therapies (e.g. photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
- •GROUP II (low need”) patients:
- •Adult patients with moderate to severe plaque psoriasis who have undergone pre-treatment with no more than one currently available systemic therapy (e.g. photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
- •7. Patients must have had a chest x-ray (preferably posteroanterior and lateral) within 3 months prior to first infusion with no evidence of malignancy, infection (e.g. tuberculosis) or fibrosis.
- •8. Laboratory test results: liver enzymes (AST, ALT, GGT and alkaline phosphatase) must be within 1.5 times the upper limit of normal range (ULN), total bilirubin = 1.0 ULN, serum creatinine < 1,5 mg/dl (must be available at baseline).
- •9. Patients must agree to avoid prolonged sun exposure or other ultraviolet light sources during the study.
- •10. Women of child-bearing potential must agree to use a medically accepted method of contraception prior to screening, while receiving protocol-specified medication, and for six months after stopping the medication. Acceptable methods of contraception include abstinence, condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, oral or injectable hormonal contraceptive, and surgical sterilization (e.g. hysterectomy or tubal ligation).
- •11. Women of child-bearing potential must have a negative serum pregnancy test (beta-hCG) at Screening (must be available at Baseline).
- •Patient Inclusion Criteria at Baseline Visit (Visit 1)
- •1. Baseline PASI- Score of 12 or greater
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient Exclusion Criteria
- •The patient will be excluded from entry if ANY of the criteria listed below are met:
- •Patient Exclusion Criteria at Screening Visit (Visit 0)
- •Prior and Concomitant Diseases
- •1. Patients suffering from active or latent tuberculosis. Prior to the start of treatment with infliximab tuberculosis needs to be excluded following the recommendations published by the German Paul Ehrlich Institut.
- •2. Patients who have had or have a serious infection (e.g. abscess, pneumonia or pyelonephritis) or who have been hospitalized or received treatment with i.v. antibiotics during the previous 2 months.
- •3. Patients who are known to be infected with human immunodeficiency virus, hepatitis B or C virus, prior or current opportunistic infections (within the last six months, H. zoster within the last 2 months).
- •4. Patients suffering from congestive heart failure including medically controlled asymptomatic patients.
- •5. History of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis.
- •6. Patients who have current signs and symptoms or history of systemic lupus erythematosus.
- •7. Patients suffering from non-plaque psoriasis, e.g. erythrodermic, guttate or pustular forms. The presence of psoriasis-arthritis is no exclusion criterion.
- •8. Patients suffering from current drug induced psoriasis (e.g. a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers or calcium-channel-blockers). If the patient takes one of those substances on aregular basis, it should be on a stable dose for at least three weeks prior to baseline.
- •9. Patients suffering from severe, progressive or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral or psychiatric diseases, that, in the opinion of the investigator, would interfere with the study evaluations or safe or optimal participation in the study.
- •10. Any known malignancy during the last five years (except basal cell carcinoma), any history of lymphoproliferative disease.
- •Prior Medication
- •11. Patients who have received any systemic psoriasis therapy (e.g. immunosuppressant) or lithium within 28 days of baseline visit.
- •12. Patients pretreated with etanercept or efalizumab within 28 days of Baseline.
- •13. Patients previously treated with infliximab.
- •14. Patients who have used topical treatments that could affect PASI evaluation (e.g. corticosteroids, anthralin, topical vitamin D derivates) within 2 weeks of baseline visit, except special areas like head or hands.
- •15. Patients who have used any investigational drug within 3 months of Baseline.
- •16. Patients with allergy/sensitivity to study drug or its excipients.
- •17. Women who are breast-feeding, pregnant, or intend to become pregnant.
- •18. Patients with any clinically significant condition or situation, other than the condition being studied.
- •19. Patients who are participating in any other clinical study.
- •20. Patients who are part of the staff personnel directly involved with this study.
- •21. Patients who are a family member of the investigational study staff.
- •Patient Exclusion Criteria at Baseline Visit (Visit 1)
- •1. Patients who have used any investigational drug within 3 months before baseline.
- •2. Patients who have received any systemic psoriasis therapy (e.g. immunosuppressant) or lithium within 28 days of baseline visit.
- •3. Patients pretreated with etanercept or efalizumab within 28 days of Baseline.
- •4. Patients who have used topical trea
研究者
相似试验
进行中（未招募）
1 期
Estudio de no inferioridad, en grupos paralelos, multicéntrico, aleatorizado y abierto de las inyecciones subcutáneas de RO0503821 administradas una vez al mes comparado con darbepoetin alfa administrado de acuerdo con la información declarada en la ficha técnica del producto en pacientes con nefropatía crónica que no están en diálisis. - STELLATAefropatía crónicaMedDRA version: 8.1Level: LLTClassification code 10058124Term: Nephrogenic anemiaEUCTR2006-004552-21-ESF. Hoffmann-La Roche Ltd200
招募中
不适用
The Felix Study: Assessing the Felix™ System vs Swim-Up and Discontinuous Gradient Centrifugation to isolate spermatozoa for use in assisted reproductive technologymale infertility factorassisted reproductive technologyReproductive Health and Childbirth - Fertility including in vitro fertilisationACTRN12622000439741Memphasys Limited104
尚未招募
3 期
The Combination of Tirzepatide and Resistance EXercise (T-REX) for the Management of Body CompositioObesityACTRN12623001236684The University of Western Australia120
尚未招募
Unknown
Efficacy of individualized homoeopathic remedies in cases of pica in paediatric age groupCTRI/2023/03/050594Deepti Sharma
尚未招募
1 期
COMPARATIVE STUDY BETWEEN TWO GROUPS,BOTH GROUPS RECEIVING DIFFERENT DRUG COMBINATIONS, IN PATIENTS UNDERGOING ERCPCTRI/2023/08/057038Department of Anaesthesiology